ArticleTransplant infectious disease : an official journal of the Transplantation Society
Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Making Sense of Mollicute Screening in Lung Transplant Recipients: Challenges and Opportunities.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
- Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetamycoplasma hominis and Ureaplasma species (Mollicutes) can cause clinically significant Mollicute infections (csMI) early after lung transplantation (LT). Mollicute infection is associated with hyperammonemia syndrome (HS), a complication resulting in cerebral edema and death. We sought to describe the results before and after a screening protocol to detect and preemptively treat Mollicutes early after LT.
methodsWe retrospectively reviewed LT data at our institution before (January 1, 2020-September 4, 2022) and after (September 5, 2022-August 31, 2023) a screening protocol to detect Mollicutes by PCR on bronchoalveolar lavage within 24 h post-LT and serum ammonia monitoring every 48 h. Antibiotics were initiated for ammonia > 60 µmol/L or if PCR+. We assessed risk factors and recipient outcomes for Mollicute PCR+ and PCR-. We compared the incidence of HS and csMI in the protocol and pre-protocol groups.
resultsScreening detected Mollicutes in 24/125 (19.2%). All were treated ≥ 14 days. On multivariable analysis, donor age ≤ 40 years was associated with PCR+ (OR: 4.28, 95% CI: 1.65-12.13, p = 0.004). There were no differences in 6-month mortality (8.3% vs. 7.9%, p = 0.61), 3-month rejection (46% vs. 37%, p = 0.19), or mean ICU length of stay (35 days [SD = 29] vs. 42 days [SD = 54], p = 0.14) between PCR+ and PCR-. csMI occurred in 1/125 (0.8%) in the protocol group with no HS. Pre-protocol, 15/1373 (1.09%) developed csMI or HS with two deaths from HS.
conclusionsMollicute detection by PCR screened early post-LT was inversely associated with donor age. Preemptive treatment for Mollicute detection and elevated ammonia in the early posttransplant setting may prevent serious donor-derived infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.